相关实验视频
Updated: Mar 15, 2026

10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
33.6K
眼球半衰期:它对内抗血管新生药物耐用性的作用和不作用
Robert Avery1, Cheikh Diack2, Nancy Holekamp2
1California Retina Consultants, Santa Barbara, CA, USA.
Ophthalmology and therapy
|March 13, 2026
概括
本评论探讨了眼球半衰期如何影响使用抗血管生成疗法治疗视网膜疾病的治疗耐久性. 它检查了aflibercept剂量对眼球清除和半衰期的影响,以制定更好的治疗策略.
科学领域:
- 眼科医生 眼科 眼科
- 药理动力学 药理动力学
- 视网膜疾病 视网膜疾病
背景情况:
- 静脉内注射的抗血管性疗法对于视网膜疾病至关重要,如新血管与年龄相关的黄斑变性和糖尿病黄斑.
- 治疗的持久性是管理这些慢性疾病的患者和临床医生的关键问题.
研究的目的:
- 建立一个概念框架,将眼球半衰期与治疗耐久性联系起来,用于内抗血管生成疗法.
- 批判性地评估有关aflibercept剂量,眼球清除和半衰期的说法.
- 在视网膜疾病治疗中,对影响治疗持续时间的因素提供基于证据的理解.
主要方法:
- 药物动力学原理的概念分析.
- 对内抗血管性疗法现有数据的审查.
- 关于阿弗利塞普特药理动学的科学文献的批判性审查.
主要成果:
- 眼球半衰期是治疗耐久性的重要决定因素.
- 有证据表明,增加aflibercept剂量可能不会像声称的那样比例地降低眼球清除率或延长半衰期.
- 药物动力学因素在确定眼部抗血管生成治疗的有效持续时间方面发挥着复杂的作用.
结论:
- 了解眼球半衰期和药理动力学之间的相互作用对于优化抗血管生成疗法方案至关重要.
- 需要进一步的研究来澄清内药物的剂量-药理动力学-耐久性关系.
- 基于证据的见解可以指导临床决策,以提高视网膜疾病患者的治疗结果.
相关概念视频
Ophthalmic Drug Delivery Systems
154
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
154
Angle Closure Glaucoma: Treatment
1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
70
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
70
Glaucoma: Overview
1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
75
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
75

